GH peptide blends compared in the current research literature almost always come down to a single design decision: which growth-hormone-releasing-hormone (GHRH) analog is paired with the ghrelin-mimetic secretagogue ipamorelin. Two combinations dominate laboratory catalogs and preclinical study designs — CJC-1295 without DAC + Ipamorelin and Tesamorelin + Ipamorelin. Both exploit the same two-receptor synergy, but they differ in component ratio, GHRH-analog stability, and the specific research questions they are used to investigate. This article compares them strictly as research reagents.
Research Use Only (RUO): The compounds discussed here are for laboratory and in-vitro/preclinical research use only. They are not for human or veterinary use, are not intended to diagnose, treat, cure, or prevent any disease, and have not been evaluated by the FDA. Nothing below is medical advice or a human dosing protocol.
The shared mechanism behind both blends
Both blends combine two orthogonal signaling arms that converge on somatotroph cells of the anterior pituitary. Understanding the shared pathway makes the differences easier to interpret. For deeper background, see our GHRH + ghrelin synergy in GH research overview.
- GHRH-analog arm (CJC-1295 or Tesamorelin): binds the GHRH receptor (GHRHR), a Gs-coupled GPCR, elevating intracellular cAMP and driving synthesis and release of growth hormone (GH).
- Ghrelin-mimetic arm (Ipamorelin): a selective agonist of the growth hormone secretagogue receptor (GHS-R1a), acting through the Gq/phospholipase-C/IP3 pathway to mobilize intracellular calcium and amplify the GH pulse.
Because the two receptors use distinct second-messenger cascades, research models frequently report supra-additive (synergistic) GH release when the arms are combined, alongside suppression of somatostatin tone. Ipamorelin's selectivity is a key reason it appears in both blends: in preclinical models it releases GH with minimal effect on cortisol, prolactin, or ACTH, which reduces confounding variables when GH output is the measured endpoint.
Component ratios and pharmacokinetics compared
The clearest distinction between the two blends is the GHRH analog itself and the molar/mass ratio at which it is combined with ipamorelin.
| Attribute | CJC-1295 no DAC + Ipamorelin | Tesamorelin + Ipamorelin |
|---|---|---|
| GHRH analog | CJC-1295 without DAC (mod-GRF 1-29) | Tesamorelin (trans-3-hexenoyl GRF 1-44) |
| Typical labeled ratio | ~1:1 (e.g., 5 mg : 5 mg) | GHRH-weighted (e.g., ~10 mg : 3.3 mg) |
| GHRH-arm half-life (research reports) | Short, ~30 min; pulsatile profile | Longer, ~26–38 min plasma but greater metabolic stability |
| Structural stabilization | 4 amino-acid substitutions resist DPP-IV cleavage | N-terminal hexenoyl group resists enzymatic degradation |
| Signaling character | Emulates native pulsatile GHRH signaling | Robust, well-characterized GHRHR agonism |
Why the ratio differs
The near-1:1 loading in the CJC-1295 no DAC blend reflects a design goal of balancing a short, physiologically "pulsatile" GHRH signal with an equally weighted ghrelin-mimetic amplifier — a configuration studied for its resemblance to native GH secretion dynamics. The GHRH-weighted ratio in the Tesamorelin blend reflects tesamorelin's role as the primary, extensively characterized GHRH driver, with ipamorelin present as a pulse-amplifying co-agonist rather than an equal partner. Featured research preparations include CJC-1295 no DAC + Ipamorelin 5/5 mg and Tesamorelin + Ipamorelin 13.3 mg.
Distinct research focuses
The choice of GHRH analog also tends to track with the scientific questions each blend is used to model.
CJC-1295 no DAC + Ipamorelin — pulse-fidelity research
- Modeling episodic, pulsatile GH release and how pulse frequency versus amplitude influences downstream IGF-1 signaling in vitro.
- Comparing "no DAC" (short) versus DAC-bearing (long-acting) GHRH kinetics on somatotroph responsiveness and receptor desensitization.
- Studying selectivity — because ipamorelin spares cortisol/prolactin pathways, it isolates GH-axis effects. See CJC-1295 no DAC + Ipamorelin blend research.
Tesamorelin + Ipamorelin — metabolic and adipose-axis research
- Tesamorelin is the most studied GHRH analog in the context of visceral adipose tissue and lipid metabolism models, making this blend common in metabolic-pathway research.
- Investigating GH/IGF-1 axis modulation of lipolysis-related signaling in cell and tissue models.
- Examining whether adding ipamorelin's calcium-driven pulse amplification changes GH output relative to tesamorelin alone. See Tesamorelin/Ipamorelin blend research guide.
Choosing a blend for a research model
For laboratory planning, the decision typically reduces to a few variables. If the endpoint is pulse fidelity, GHRH kinetics, or receptor desensitization, the balanced short-acting CJC-1295 no DAC blend is the more direct tool. If the endpoint is metabolic or adipose-axis signaling, the tesamorelin-weighted blend aligns with the larger existing literature on that analog. Researchers isolating a single arm's contribution often run each component separately as controls — our Ipamorelin vs CJC-1295 research comparison covers those single-agent baselines, and the peptide blends overview explains the rationale for combining compounds at all.
Laboratory handling of GH secretagogue blends
Both blends are supplied as lyophilized powder for reconstitution as research preparations. General handling practices reported in the literature:
- Reconstitution: bacteriostatic or sterile water added down the vial wall; the vial is swirled, never shaken, to protect peptide integrity.
- Storage: lyophilized vials stored at −20 °C for long-term stability; reconstituted solutions refrigerated at 2–8 °C and protected from light and repeated freeze–thaw cycles.
- Purity and verification: every NeuroLabs preparation is ≥99% purity and third-party COA-tested, so mass ratios and identity can be confirmed before a study begins.
Because blends contain two peptides at a fixed ratio, the fixed stoichiometry is a feature for reproducibility but a constraint when a protocol needs independent titration of each arm — a factor worth noting during experimental design. Return to the Peptide Blends & Combination Research pillar for the full family of combination-research guides.
Summary
Both leading GH secretagogue blends pair a GHRH analog with selective ipamorelin to exploit dual-receptor GH synergy. The CJC-1295 no DAC blend uses a balanced ~1:1 ratio and short pulsatile kinetics suited to pulse-fidelity research; the tesamorelin blend uses a GHRH-weighted ratio and greater analog stability suited to metabolic-axis research. Component ratio and analog choice — not the ipamorelin arm — are the variables that differentiate them for laboratory work.